智通财经APP讯，三生制药(01530)发布截至2024年12月31日止年度业绩，该集团期内取得收入91.08亿元(人民币，下同)，同比增加16.5%;母公司拥有人应占纯利20.90亿元，同比增加34.9%;每股基本盈利0.86元;拟派发末期股息每股25港仙。
公告称，收入增加主要由于特比澳、蔓迪及赛普汀的销售额强势增长。
于2024年12月31日，集团积极研发的30项重点产品中，29项于中国内地作为创新药物开发。这些在研产品中，18项为抗体，6项为其他生物制品及6项为小分子药物。集团拥有13项血液/肿瘤科在研产品;11项在研产品目标为自身免疫疾病(包括RA)，及其他疾病，包括顽固性痛风及眼科疾病(如BRVO);3项肾科在研产品;2项皮肤科在研产品及1项代谢科在研产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.